IMRN:NASDAQImmuron Limited analysis
Data as of Sep 30, 2026 - not real-time
- Latest price
- $1.19
- Risk: high
- 9/10High risk
Summary
The moving-average structure behind Immuron Limited is bullish at $1.19, with short-term averages leading the long-term ones. Over a rolling month the price has gained 10.2%. Relative strength is 46.5 — neutral — and the MACD signal is bearish. Recent trading has carved out support near $1.06 and resistance around $1.99.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. The average analyst target implies 227.4% above today's level. Revenue is growing at 7.2% on a -47.7% profit margin.
Risk scores 9 out of 10, which is high for this asset class. With 30-day volatility of 162.4%, a beta of 0.66 and a maximum drawdown of 70.2%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
Across every horizon the signals point the same way: hold, at a conviction of 1 out of 10.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. The average analyst target implies 227.4% above today's level. Revenue is growing at 7.2% on a -47.7% profit margin.
Risk scores 9 out of 10, which is high for this asset class. With 30-day volatility of 162.4%, a beta of 0.66 and a maximum drawdown of 70.2%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
Across every horizon the signals point the same way: hold, at a conviction of 1 out of 10.
Top market events
- Shares of Immuron Limited IMRN are surging Friday morning following news that the Australian biopharmaceutical company...
- Benzinga.com2monImmuron Earnings & ForecastsImmuron IMRN last issued guidance on July 16, 2026 for fiscal year 2026....
- MELBOURNE, Australia, Sept. 04, 2026 GLOBE NEWSWIRE -- Immuron Limited ASX: IMC; NASDAQ: IMRN is pleased to announce...
Market outlook
Short term
< 1 yearNeutral
Model confidence2/102 out of 10
Key factors
- Short-term moving averages stacked above long-term ones
- Trading above the 200-day average of 1.00
- MACD momentum is negative
Medium term
1–3 yearsNeutral
Model confidence1/101 out of 10
Key factors
- Short-term moving averages stacked above long-term ones
- Trading above the 200-day average of 1.00
- Analyst targets imply +227.4% versus the current price
Long term
> 3 yearsNeutral
Model confidence1/101 out of 10
Key factors
- Negative profit margin of -47.7%
- Analyst targets imply +227.4% versus the current price
- Negative return on equity of -38.3%
Key metrics
Financial health
Revenue Growth7.20%
Profit Margin-47.71%
P/E Ratio-119.0
ROE-38.27%
ROA-19.14%
Debt/Equity1.70
P/B Ratio1.2
Op. Cash Flow$-3259720
Free Cash Flow$-2070447
Industry P/E30.5
Technical analysis
TrendBullish
RSI46.5
Support$1.06
Resistance$1.99
MA 20$1.32
MA 50$1.20
MA 200$1.00
MACDBearish
VolumeDecreasing
Fear & Greed Index92.88
Valuation
Target Price$3.90
Upside/Downside227.37%
GradeFair
TypeBlend
Risk assessment
Beta0.66
Volatility162.37%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.